Skip to content

    Gufic BioScience

    GUFICBIOGood
    Healthcare·17 Nov 2025
    Management Summary

    Gufic Biosciences reported a strong Q2 FY26 with modest revenue growth but significant margin expansion, primarily driven by the Indore plant's commercialization and increased international business. The company is focused on scaling its complex injectable portfolio, expanding regulatory reach, and optimizing capacity utilization at the new Indore facility. While domestic critical care faced pricing erosion, specialty segments like infertility and botulin toxin showed robust growth.

    Highlights

    8
    • Total revenue for Q2 FY26 was ₹230 crores, a 1.3% QoQ increase from ₹227 crores in Q1 FY26.

    • EBITDA for Q2 FY26 increased to ₹37.9 crores from ₹33.2 crores in Q1 FY26, a 14.16% QoQ growth.

    • EBITDA margin improved to 16.45% in Q2 FY26 from 14.63% in Q1 FY26.

    • Profit Before Tax (PBT) rose to ₹20.5 crores in Q2 FY26 from ₹16.3 crores in Q1 FY26, a 25.77% QoQ increase.

    • PBT margin improved to 8.9% in Q2 FY26 from 7.18% in Q1 FY26.

    • Profit After Tax (PAT) for Q2 FY26 was ₹14.9 crores, up 23.14% QoQ from ₹12.1 crores in Q1 FY26.

    • PAT margin improved to 6.47% in Q2 FY26 from 5.32% in Q1 FY26.

    • International business grew by 32-33% QoQ, driven by new market openings and tenders.

    Key financials

    Single quarter

    07 metrics
    1. 01Revenue₹230 Cr+1.3%QoQ
    2. 02EBITDA₹37.9 Cr+14.2%QoQ
    3. 03EBITDA Margin16.4%
    4. 04PBT₹20.5 Cr+25.8%QoQ
    5. 05PBT Margin8.9%

    Segment breakdown

    International Business
    32% Growth
    Ferticare (Infertility)
    18% Growth₹25 Cr Annual Run Rate (Puregraf)₹15 Cr Annual Run Rate (Supergraf)₹10 Cr Annual Run Rate (Guficin Alpha)
    Critical Care & Sparsh (Domestic)
    8% Value Growth4% Net Growth (after erosion)
    Healthcare Business & Zenova
    10% Growth Trajectory
    Botulin Toxin (Neuro & Aesthetic)
    22% Growth
    List

    Guidance & targets

    17
    CategoryTargetPriority
    Profitability
    Indore Plant EBITDA Break-even
    Break-even
    High
    Profitability
    Indore Plant Margin Accretive
    Margin Accretive
    High
    Profitability
    Meropenem Bag Premium
    15%
    High
    Profitability
    Gross Margin
    at least 20%
    Medium
    Profitability
    Gross Margin (with increased international sale ratio)
    21-22%
    Low
    Regulatory Approvals
    Indore Plant EU GMP and UK MHRA Approval
    Approval
    High
    Revenue
    CMO Business Revenue Contribution
    Full revenue captured
    Medium
    Revenue
    Indore Plant Topline at 70-80% Capacity Utilization
    ₹750-800 crores
    High
    Revenue
    Ferticare (combined Ferticare & Fertimax) Revenue
    ₹100+ crores
    High
    Revenue
    Botulin Toxin India Market Revenue Target
    ₹100 crore level
    Medium
    Capex
    Total CAPEX for Indore
    ₹350-355 crores
    High
    Debt
    Borrowing Reduction
    ₹300-350 crores
    High
    Revenue Growth
    Ferticare (Infertility) Division Growth
    15-20%
    Medium
    Revenue Growth
    International Business Growth
    15-20%
    Medium
    Revenue Growth
    Critical Care Growth (with erosion)
    8-10%
    Medium
    Capacity Utilization
    Indore CMO Client Onboarding
    50% of 12-14 major clients
    Medium
    Product Launch
    New CMO Product Lines (vials & ampoules)
    Kicking in
    Medium

    Risks & concerns

    4
    RiskSeverity

    API price downward strength and pricing erosion in Critical Care/Sparsh

    Net growth in Critical Care and Sparsh is 4-6% despite higher unit growth due to price erosion, impacting topline.Management acknowledged

    medium

    CMO business suffering due to capacity prioritization for exports

    CMO business has suffered in the first six months as capacity was focused on exports, with a shift to Indore being a long process due to audits and validation.Management acknowledged

    medium

    Transition risk for CMO clients shifting to Indore facility

    Clients build up 3 months of inventory from Navsari before shifting to Indore to manage transition risks and troubleshooting, impacting immediate revenue ramp-up from Indore.Management acknowledged

    medium

    High upfront costs and bandwidth requirements for international expansion of Botulin Toxin

    Entering international markets for botulin toxin requires significant upfront investment for regulatory processes, clinical data generation, and building dedicated bandwidth, leading to a delayed international push for this product.Management acknowledged

    medium

    Q&A highlights

    3

    “And I think you're right. I think mostly we discuss it during the investor call, but if it's in the form of a PowerPoint representation, it will really be able to track that on a Q2Q basis. Fine. So, I really got that message. So, I will ask my team also to work on that.”

    Analyst requested more granular financial data by Strategic Business Unit (SBU) for better tracking, and management agreed to implement this, indicating improved future transparency.

    asked by Nitin Gosar, Bank of India Mutual Fund

    2 min read6 chapters

    Detailed Narrative

    01

    Q2 FY26 Financial Performance and Margin Expansion

    Gufic Biosciences reported a modest 1.3% sequential revenue growth to ₹230 crores in Q2 FY26. However, profitability saw significant improvement, with EBITDA increasing by 14.16% QoQ to ₹37.9 crores, and EBITDA margin expanding to 16.45% from 14.63%. PAT also grew by 23.14% QoQ to ₹14.9 crores, with PAT margin reaching 6.47%. This margin expansion was attributed to a higher contribution from the international business and improved sales mix.

    02

    Indore Facility Scale-up and Outlook

    The Indore plant, which began commercial invoicing in October 2024 (Q1 FY26), is progressing as per plan, with 40 products having completed tech transfers and an additional 27 under development. Management expects the facility to achieve EBITDA break-even by Q4 FY26 and become margin accretive by FY27 onwards. The total CAPEX for Indore is around ₹350-355 crores, with a projected topline of ₹750-800 crores at 70-80% capacity utilization. EU GMP and UK MHRA approvals are targeted for Q1 FY27.

    03

    Domestic Business Segment Performance

    The domestic business showed mixed performance. The infertility division (Ferticare) is a key growth driver, with Puregraf trending towards a ₹25 crore annual run rate and Supergraf towards ₹15 crore. Critical Care and Sparsh segments are growing at 8-10% in value, but net growth is 4-6% due to API price erosion. The healthcare business and Zenova are on a 10-15% growth trajectory. The Botulin Toxin business (Neuro & Aesthetic) is growing robustly at 22%.

    04

    International Business Expansion and Strategy

    The international business demonstrated strong growth of 32-33% QoQ, driven by new market entries in regions like Canada, South Africa, and Brazil. Gufic Ireland secured its first marketing authorization in the EU, establishing a platform for future filings. The company received 24 key product and facility approvals across regulated and emerging markets. The strategy involves a disciplined, compliance-led approach to scale its complex injectable portfolio internationally, targeting 15-20% year-on-year growth.

    05

    Toxin Platform (Aesthaderm & Neurocare) Strategy

    The Aesthaderm platform is expanding from toxins into a fuller aesthetic ecosystem, including fillers and bio-stimulators, with in-licensing for global quality products underway. Neurocare, the therapeutic toxin, focuses on creating new injectors and expanding indications. Management noted the Indian toxin market is small (₹18-20 million) but aims for a ₹100 crore business level, while acknowledging high upfront costs for international regulatory and clinical data for global expansion.

    06

    Capital Allocation and Debt Management

    The company has no major CAPEX plans for the next two years. Current borrowing, including working capital and term loans, stands at ₹350-360 crores. Management expects this to reduce to ₹300-350 crores within two years, with additional working capital requirements for the Indore plant to be met through internal revenue generation. This indicates a focus on deleveraging and internal funding for growth.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.